** Johnson & Johnson JNJ.N halved its expectations for costs this year related to new tariffs and raised full-year sales and profit forecast on Wednesday after a strong quarter for its flagship cancer drug Darzalex and cardiovascular devices
INNOVATIVE MEDICINES SEGMENT TO LEAD GAINS
** J.P.Morgan ("neutral," PT: $185) says JNJ's underlying business is well positioned and capable of generating over 5% revenue growth with the innovative medicines segment and medtech portfolio supporting growth
** Morningstar (fair value: $172) says on potential pharmaceutical tariffs, JNJ is in a good position with most US-bound products already made in the U.S.
** TD Cowen ("buy," PT: $185) notes JNJ has numerous milestones ahead in the innovation medicine pipeline including TAR-200 for bladder cancer that is set to be commercialized later this year
** Leerink Partners ("market perform," PT: $171) says TAR-200 is well positioned to gain significant market share, aiding co's growth prospects
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.